Sorrento Therapeutics has received approval and an import license from COFEPRIS Mexico for the COVI-STIX test. The company is now establishing a subsidiary, Sorrento Mexico, to manage commercial operations in Mexico. COVI-STIX is a diagnostic test for detection of the virus nucleocapsid antigen. The first shipments of COVI-STIX will begin in July 2021.